149 related articles for article (PubMed ID: 32020517)
21. BMP9-ID1 Signaling Activates HIF-1α and VEGFA Expression to Promote Tumor Angiogenesis in Hepatocellular Carcinoma.
Chen H; Nio K; Tang H; Yamashita T; Okada H; Li Y; Doan PTB; Li R; Lv J; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163396
[TBL] [Abstract][Full Text] [Related]
22. The Role of Angiogenesis in Hepatocellular Carcinoma.
Morse MA; Sun W; Kim R; He AR; Abada PB; Mynderse M; Finn RS
Clin Cancer Res; 2019 Feb; 25(3):912-920. PubMed ID: 30274981
[TBL] [Abstract][Full Text] [Related]
23. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
Jouve JL; Lecomte T; Bouché O; Barbier E; Khemissa Akouz F; Riachi G; Nguyen Khac E; Ollivier-Hourmand I; Debette-Gratien M; Faroux R; Villing AL; Vergniol J; Ramee JF; Bronowicki JP; Seitz JF; Legoux JL; Denis J; Manfredi S; Phelip JM;
J Hepatol; 2019 Sep; 71(3):516-522. PubMed ID: 31125576
[TBL] [Abstract][Full Text] [Related]
24. Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
Escudier B; Rini BI; Motzer RJ; Tarazi J; Kim S; Huang X; Rosbrook B; English PA; Loomis AK; Williams JA
Clin Genitourin Cancer; 2015 Aug; 13(4):328-337.e3. PubMed ID: 25816720
[TBL] [Abstract][Full Text] [Related]
25. Early decrease in serum amphiregulin or vascular endothelial growth factor levels predicts sorafenib efficacy in hepatocellular carcinoma.
Godin C; Bodeau S; Saidak Z; Louandre C; François C; Barbare JC; Coriat R; Galmiche A; Sauzay C
Oncol Rep; 2019 Mar; 41(3):2041-2050. PubMed ID: 30569112
[TBL] [Abstract][Full Text] [Related]
26. A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007-2015.
Huang CC; Chen HY; Chang RH; Liao PA; Lien HH; Hung CS; Yang SS; Hu JT
Drug Des Devel Ther; 2019; 13():397-404. PubMed ID: 30774305
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Sorafenib in Unresectable Hepatocellular Carcinoma with Bile Duct Invasion.
Tanaka T; Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
Oncology; 2020; 98(9):621-629. PubMed ID: 32434180
[TBL] [Abstract][Full Text] [Related]
28. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
[TBL] [Abstract][Full Text] [Related]
29. A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.
Goyal L; Zheng H; Abrams TA; Miksad R; Bullock AJ; Allen JN; Yurgelun MB; Clark JW; Kambadakone A; Muzikansky A; Knowles M; Galway A; Afflitto AJ; Dinicola CF; Regan E; Hato T; Mamessier E; Shigeta K; Jain RK; Duda DG; Zhu AX
Clin Cancer Res; 2019 Jan; 25(1):80-89. PubMed ID: 30190369
[TBL] [Abstract][Full Text] [Related]
30. Antiangiogenic therapies for advanced hepatocellular carcinoma.
Sampat KR; O'Neil B
Oncologist; 2013; 18(4):430-8. PubMed ID: 23576483
[TBL] [Abstract][Full Text] [Related]
31. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
Bianconi M; Faloppi L; Loretelli C; Zizzi A; Giampieri R; Bittoni A; Andrikou K; Del Prete M; Burattini L; Montironi R; Scartozzi M; Cascinu S
Oncotarget; 2016 Jun; 7(25):37599-37607. PubMed ID: 27175586
[TBL] [Abstract][Full Text] [Related]
32. Sulforaphane exerts anti-angiogenesis effects against hepatocellular carcinoma through inhibition of STAT3/HIF-1α/VEGF signalling.
Liu P; Atkinson SJ; Akbareian SE; Zhou Z; Munsterberg A; Robinson SD; Bao Y
Sci Rep; 2017 Oct; 7(1):12651. PubMed ID: 28978924
[TBL] [Abstract][Full Text] [Related]
33. The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularization.
Zeng W; Gouw AS; van den Heuvel MC; Zwiers PJ; Zondervan PE; Poppema S; Zhang N; Platteel I; de Jong KP; Molema G
Hepatology; 2008 Nov; 48(5):1517-27. PubMed ID: 18924243
[TBL] [Abstract][Full Text] [Related]
34. Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development.
Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H
Oncol Rep; 2005 May; 13(5):853-7. PubMed ID: 15809749
[TBL] [Abstract][Full Text] [Related]
35. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.
Scartozzi M; Bianconi M; Faloppi L; Loretelli C; Bittoni A; Del Prete M; Giampieri R; Maccaroni E; Nicoletti S; Burattini L; Minardi D; Muzzonigro G; Montironi R; Cascinu S
Br J Cancer; 2013 Mar; 108(5):1126-32. PubMed ID: 23511629
[TBL] [Abstract][Full Text] [Related]
36. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
Park JW; Kim YJ; Kim DY; Bae SH; Paik SW; Lee YJ; Kim HY; Lee HC; Han SY; Cheong JY; Kwon OS; Yeon JE; Kim BH; Hwang J
J Hepatol; 2019 Apr; 70(4):684-691. PubMed ID: 30529387
[TBL] [Abstract][Full Text] [Related]
37. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
[TBL] [Abstract][Full Text] [Related]
38. The epigallocatechin gallate derivative Y
Liao ZH; Zhu HQ; Chen YY; Chen RL; Fu LX; Li L; Zhou H; Zhou JL; Liang G
J Ethnopharmacol; 2020 Sep; 259():112852. PubMed ID: 32278759
[TBL] [Abstract][Full Text] [Related]
39. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
40. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
Weintraub JL; Salem R
J Vasc Interv Radiol; 2013 Aug; 24(8):1123-34. PubMed ID: 23562168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
